Pulmonary vascular disease & thromboembolism

Mechanical Thrombectomy vs Catheter-Directed Thrombolysis for High-Risk Pulmonary Embolism: A Target Trial Emulation

JACC AdvPublished observational study

Main finding · 1-year mortalityResult — go to the resultAdjusted hazard ratio 1.16 95% CI 0.84–1.59

Authors' conclusion

Among older adults with high-risk PE treated with catheter-based therapies, the clinical outcomes were similar between the patients treated with MT vs CDT. Randomized trials are needed to confirm our findings.

Study context

Population
Medicare fee-for-service beneficiaries aged 65 to 99 years admitted with high-risk pulmonary embolism (PE) (defined by cardiac arrest, shock, and vasopressor use) who underwent mechanical thrombectomy (MT)/catheter-directed thrombolysis (CDT) from 2017 to 2020
Participants
235 vs 484
Exposure
MT vs CDT
  • MTn = 235
  • CDTn = 484reference
Outcome
1-year mortality
Follow-up
1 year
Methodological detailstarget trial emulation framework, inverse probability of treatment weighting approach, controlling for 62 baseline covariates
  • Target trial emulation framework
  • Inverse probability of treatment weighting approach, controlling for 62 baseline covariates

Main finding

As reported in the abstract

Adjusted hazard ratio

1.16

95% CI 0.84–1.59

By group

MTvs CDT
adjusted HR 1.16 (95% CI 0.84–1.59)

Observational data: associations, not effects.

Further findings

OutcomeSubdistribution HR (95% CI)
All-cause readmissionNo evidence of significant difference0.89 (0.56–1.40)

Safety

OutcomeAdjusted OR (95% CI)
Intracranial hemorrhage · in-hospitalNo evidence of significant difference0.36 (0.07–1.77)
Transfusions · in-hospitalNo evidence of significant difference0.96 (0.52–1.76)

Original publication

Mechanical Thrombectomy vs Catheter-Directed Thrombolysis for High-Risk Pulmonary Embolism: A Target Trial Emulation. JACC Adv. Published 24 March 2025. doi:10.1016/j.jacadv.2025.101706

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.